Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Researchers at Weill Cornell Medicine have built a computer model that could dramatically speed up the design of protein degrader therapies — a promising approach for treating cancer. Instead of relying on slow, costly trial-and-error lab work, the model uses basic lab measurements to predict how well a degrader will work inside a cell. The team hopes it could shave years off the drug development process.
Researchers at Weill Cornell Medicine have developed a mathematical computer model designed to streamline the development of protein degrader therapies — a cutting-edge class of treatments that destroy disease-causing proteins entirely, rather than just disabling them. Published in Nature Communications, the study could potentially cut years off the drug development timeline.
Unlike traditional drugs that block a protein's function, protein degraders hijack the cell's own disposal machinery to eliminate harmful proteins altogether. This is especially valuable in cancer, where mutations can cause proteins to multiply to dangerous levels — sometimes 10 times their normal count — making simple inhibition insufficient.
The new model, developed by Dr. Wei Du under the direction of Dr. Olivier Elemento, uses readily available lab measurements to predict degrader performance in a simulated cell environment, helping scientists identify the best protein targets and optimize degrader design without exhaustive lab experimentation.
Key Takeaways:
Why it matters: Protein degraders represent a major frontier in precision oncology, and this modeling tool could make their development faster, cheaper, and more targeted — bringing personalized cancer treatments closer to reality.
